ArticleArthritis research & therapy2025
Baricitinib could improve the prognosis of anti-MDA5 antibody positive dermatomyositis associated interstitial lung disease.
Article in Arthritis research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Flares and definition of worsening in inflammatory myopathies: a narrative review of the literature.Rheumatology (Oxford, England) · 2026Review
- High-resolution computed tomography assessment of connective tissue disease-associated interstitial lung disease: Advances in diagnosis and prognostic evaluation.World journal of radiology · 2026Review
- Article
- Article
- Review
- Case Report: Glucocorticoids with Early Aggressive Rituximab and Upadacitinib regimen in the treatment of three patients with anti-MDA5 dermatomyositis-associated interstitial lung disease.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveCurrently, there are only a few effective treatments for anti-melanoma differentiation-associated gene 5 antibody (anti-MDA5) positive dermatomyositis (DM)-associated interstitial lung disease (ILD). The aim of this study was to evaluate the efficacy and safety of baricitinib in patients with MDA5 + DM-ILD.
methodsThe study was a retrospective cohort design that evaluated patients with MDA5 + DM-ILD who had received or not received baricitinib. Clinical symptoms, laboratory data, and survival were compared in the two groups.
resultsThirty-nine patients with MDA5 + DM-ILD who received baricitinib were included in the study. After baricitinib therapy, 31 patients (79.5%) had a clinical improvement that included Gottron’s sign (p < 0.001), heliotrope rash (p < 0.001), and dyspnea (p = 0.003). The median HRCT score decreased from 115 to 97.5 (p < 0.001), while the FVC improved significantly (76.44% vs. 90.73%, p < 0.001). In addition, serum ferritin levels (739.9 ng/ml vs. 56.3 ng/ml, p < 0.001) and lactate dehydrogenase (LDH) levels (313 U/L vs. 233 U/L, p = 0.003) decreased significantly. Notably, lymphocyte counts increased significantly, CD4 + T cells (354 cells/µl vs. 663 cells/µl, p < 0.001), and CD8 + T cells (180 cells/µl vs. 449 cells/µl, p < 0.001). Furthermore, the glucocorticoid dose reduced significantly from 40 mg daily to 10 mg daily (p < 0.001). Compared with the control group, the baricitinib group had a greater six-month survival (87.2% vs. 70%, p = 0.047). While first-line baricitinib showed a superior survival rate compared to conventional therapy (84.6% vs. 52.9%, p = 0.046).
conclusionThis study indicates that Baricitinib is a potential therapeutic for MDA5 + DM-ILD, reducing LDH and ferritin, ameliorating ILD progression, and improving survival, with first-line use may provide a significant survival advantage. However, larger prospective controlled studies are required to evaluate its efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.